Journal
PROTEIN AND PEPTIDE LETTERS
Volume 20, Issue 4, Pages 412-423Publisher
BENTHAM SCIENCE PUBL LTD
DOI: 10.2174/092986613805290372
Keywords
Type I interferons; interferon-alpha; interferon-beta; STATs; mTOR; pegylated interferons; farnesyltransferase inhibitors; EGF-R
Categories
Funding
- Associazione Italiana per la Ricerca sul Cancro [AIRC-MFAG-5695]
- AIRC-MFAG fellowship
- MIUR
Ask authors/readers for more resources
Type I interferons (IFNs) represent a group of cytokines that act through a common receptor composed by two chains (IFNAR-1 and IFNAR-2). Several in vitro and in vivo studies showed a potent antitumor activity induced by these cytokines. IFN-alpha, the first cytokine to be produced by recombinant DNA technology, has emerged as an important regulator of cancer cell growth and differentiation, affecting cellular communication and signal transduction pathways. IFN-alpha, is currently the most used cytokine in the treatment of cancer. However, the potential anti-tumour activity of IFN-alpha is limited by the activation of tumour resistance mechanisms. This article reviews the current knowledge about the antitumor activity of type I IFNs, focusing on new potential strategies able to strengthen the antitumor activity of these cytokines.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available